INFO & CONTACTS:  +39 02 2390 1

A Phase I/II, Open-label, Multicenter Study of ALE.P03 (Claudin-1 Targeted Antibody-drug Conjugate) as a Monotherapy in Adult Patients with Selected Advanced or Metastatic CLDN1+ Solid Tumors

Phase: Phase I-II clinical trials

Principal Investigator: Dott.ssa Damian Silvia

Main Facility: Oncologia Medica 1

Drug: ALE.P03

Pathologies: Colorectal cancer (CRC), Lung cancer, Cervical tumor, Urological cancers (kidney, bladder, urinary tract, others)

ClinicalTrials.gov: Read the details about clinical trials

Study designed to assess the safety and efficacy of ALE.P03 (Claudin-1 Targeted Antibody-Drug Conjugate) in monotherapy in adult patients with selected advanced or metastatic CLDN1+ solid tumors.  

The study includes two parts: a dose escalation phase (Part I) and a dose expansion phase (Part II) with a selected dose. 

Last update: 21/04/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe